Uncategorized
Spark reports $22.1 million in revenue in 2015
Spark Therapeutics reported $22.1 million in revenue in 2015, which included a $15 million milestone payment from Pfizer that was earned in December 2015, according to a company press release. Research and development expenses were reported at $46 million in 2015 compared with $16.4 million in 2014. The increase included $24.3 million in internal research and development expenses and $5.3 million in external research and development, which included $2.1 million in expenses related to clinical trials for SPK-RPE65, SPK-CHM and SPK-FIX. The SPK-RPE365 gene therapy platform is in development to (Read more...)